A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)
暂无分享，去创建一个
S. Verstovsek | R. Mesa | G. Barosi | A. Vannucchi | F. Passamonti | C. Harrison | H. Al-Ali | N. Vianelli | F. Cervantes | S. Rose | M. Bonifacio | G. Benevolo | T. Wróbel | M. Loschi | Jun Zhang | J. Kiladjian | Vishwanath Gharpure | C. Hernandez